Maintenance Notice (4:00 AM November 1 - 9:30 AM November 1, 2025): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.199
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 132866-11-6 | Product Number: L0282
Lercanidipine Hydrochloride
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 200MG |
€65.00
|
1 | 8 |
|
| 1G |
€206.00
|
1 | ≥40 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | L0282 |
Purity / Analysis Method 
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__3__6H__4__1N__3O__6·HCl = 648.20 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Light Sensitive,Heat Sensitive |
| Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image), 200MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 132866-11-6 |
| Related CAS RN
|
100427-26-7 |
| Reaxys Registry Number | 7406263 |
| PubChem Substance ID | 253660808 |
| Merck Index (14) | 5446 |
| MDL Number | MFCD07773089 |
Specifications
| Appearance | Light orange to Yellow to Green powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
Properties (reference)
| Melting Point | 195 °C(dec.) |
| Solubility (soluble in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
Transport Information:
| HS Number | 2933399999 |
Application
Paraptosis research
Reference
- Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca2+ Overload
- Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine
- L. Guarneri, P. Angelico, M. Ibba, E. Poggesi, C, Taddei, A. Leonardi, R. Testa, Arzneim.-Forsch. 1996, 46, 15.
- Lercanidipine (Rec 15/2375): a novel 1,4-dihydropyridine calcium antagonist for hypertension (a review)
- Development and evaluation of buccoadhesive controlled release tablets of lercanidipine
- Oral self emulsifying powder of lercanidipine hydrochloride: Formulation and evaluation
- Determination of lercanidipine hydrochloride and its impurities in tablets
Application
Lercanidipine Hydrochloride: A Vascular-Selective Dihydropyridine Calcium Channel Antagonist
Lercanidipine hydrochloride is a long-lasting and vascular-selective dihydropyridine calcium channel antagonist that causes vasodilatation by blocking the influx of calcium ions through L-type calcium channels in cell membranes. Recently, formulations of lercanidipine hydrochloride have been studied to improve its bioavailability. (The product is for research purpose only.)
References
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.